Angioscopy detects thrombogenic plaque from DES
Angioscopy can detect thrombogenic plaque, which result from drug-eluting stents (DES), according to a lecture by Y. Ueda, MD, cardiovascular division at the Osaka Police Hospital in Osaka, Japan. He presented in a lecture series called “Clinical Experiences with New Imaging Techniques to Detect Early DES Healing Responses in Patients” on Sunday at the Transcatheter Cardiovascular Therapeutics (TCT) conference in Washington, D.C.
In patients with drug-eluting stents, atheroscelorosis can lead to disruption, which can lead to thrombosis. Ueda suggested that the prevalence of yellow plaque is the best indicator of future thrombosis.
Ueda stressed that angiography cannot detect silent plaque rupture. Most DES (46 percent) do not cover neointima.
He said the risk of stent thrombosis can be prevented with the sealing of yellow plaque and that the industry needs to create a DES that induces good neointima, but not thrombosis.
In patients with drug-eluting stents, atheroscelorosis can lead to disruption, which can lead to thrombosis. Ueda suggested that the prevalence of yellow plaque is the best indicator of future thrombosis.
Ueda stressed that angiography cannot detect silent plaque rupture. Most DES (46 percent) do not cover neointima.
He said the risk of stent thrombosis can be prevented with the sealing of yellow plaque and that the industry needs to create a DES that induces good neointima, but not thrombosis.